IMMB Financials 07/16/2014 03:36:37 Immunotech La
Post# of 263
Posted On: 07/16/2014 4:36:34 AM
IMMB Financials 07/16/2014 03:36:37
Immunotech Laboratories, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue - -
Cost of Revenue 533 1,203
Gross Profit (533) (1,203)
Operating Expenses
Research and Development - -
Sales, General and Admin. 56 56
Non-Recurring Items - -
Other 14 14
Operating Income (603) (1,274)
Income From Continuing Operations
Add'l Income/Expense Items - -
Earnings Before Interest and Tax (626) (1,274)
Interest Expense - -
Earnings Before Tax (626) (1,274)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (626) (1,274)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (626) (1,274)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (626) (1,274)
Immunotech Laboratories, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue - -
Cost of Revenue 533 1,203
Gross Profit (533) (1,203)
Operating Expenses
Research and Development - -
Sales, General and Admin. 56 56
Non-Recurring Items - -
Other 14 14
Operating Income (603) (1,274)
Income From Continuing Operations
Add'l Income/Expense Items - -
Earnings Before Interest and Tax (626) (1,274)
Interest Expense - -
Earnings Before Tax (626) (1,274)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (626) (1,274)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (626) (1,274)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (626) (1,274)
(0)
(0)Immunotech Laboratories Inc (IMMB) Stock Research Links
Scroll down for more posts ▼